LAS VEGAS, NV - July 30, 2025 (NEWMEDIAWIRE) - NeuralBase AI Ltd. (OTC: NBBI), operating under its enterprise brand BMP AI and a growing innovator in enterprise artificial intelligence, is pleased to announce that it has executed an agreement to acquire HeartEase, a cutting-edge AI-powered diagnostic platform that uses smartphone microphones to detect early signs of heart abnormalities. This strategic acquisition marks a bold step in NeuralBase's mission to integrate wellness-focused, preventive healthcare solutions into its enterprise AI chatbot ecosystem.
With rising demand from corporations and institutions for integrated employee wellness solutions, NeuralBase recognized a growing gap in tools that go beyond mental health chatbots and provide actionable health diagnostics. HeartEase fills this need by enabling non-invasive, accessible, and real-time heart health screening through mobile devices - a perfect complement to BMP AI’s enterprise-focused chatbot technology.
"We believe that HeartEase will become a revolutionary platform as it harnesses the power of artificial intelligence and mobile technology to provide early detection of heart abnormalities. Unlike traditional diagnostics, it requires no external hardware - only a smartphone," stated Vighnesh Dobale, CEO of NeuralBase.
Key Features of HeartEase are expected to include:
- Smartphone-Only Diagnostics: Records heart sounds using the phone’s built-in microphone, removing the need for stethoscopes or peripherals.
- Global Accessibility: Designed for use in low-resource settings, rural clinics, and field health campaigns.
- Privacy-Focused: Future updates include offline diagnostic capabilities to ensure data privacy and access in disconnected areas.
- Scalable Roadmap: Plans underway to expand into AI-based screening for lung issues, anemia, and diabetes.
This targeted acquisition represents a transformational shift in how enterprises can care for their workforce. BMP AI’s chatbot platform already supports companies with intelligent task automation, HR interactions, and employee engagement tools. The addition of HeartEase allows enterprises to take employee care to a whole new level by integrating preventive health screening into the daily digital experience - right on employees’ smartphones.
“With HeartEase, we’re not just improving enterprise chatbot functionality - we’re redefining how technology can protect and empower people in their everyday lives,” added Dobale. “We see this as the foundation for a broader wellness initiative that supports both mental and physical health across global workplaces.”
The backend AI engine of HeartEase is already fully trained using validated clinical datasets, and mobile integration is underway. A Minimum Viable Product (MVP) is slated for rapid field testing in Q4 2025, with pilots targeting enterprise clients, wellness programs, and rural health campaigns.
As businesses increasingly recognize the ROI of employee wellness, from lower healthcare costs to higher productivity and retention, NeuralBase’s acquisition of HeartEase is set to deliver a unique competitive edge. It places the company at the forefront of AI-driven preventive healthcare, bridging the gap between enterprise tech and real-world impact.
With this move, NeuralBase continues its commitment to building technologies that scale ethically, inclusively, and intelligently, transforming how companies operate.
The closing of the transaction is subject to the completion of customary due diligence and the satisfaction of other closing conditions. NeuralBase will provide further updates if and when available.
Additional information about the Company is available at www.neuralbase.ai or by visiting www.sec.gov.
About NEURALBASE AI LTD.
NeuralBase AI Ltd. (OTC: NBBI) is an AI company developing secure, scalable, and context-aware conversational agents and workflow automation systems. Through its BMP AI platform - now in beta testing - the company enables organizations to streamline internal operations, enhance team collaboration, and increase productivity while maintaining strict compliance and data integrity.
Legal Disclaimer and Forward-Looking Statements
This press release contains forward-looking statements as defined under Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on current expectations, estimates, projections, and assumptions made by NeuralBase AI Ltd. (the “Company” or “NBBI”) in light of experience, current conditions, anticipated future developments, and other factors. Forward-looking statements may include words such as "aims," "anticipates," "believes," "plans," "expects," "intends," "will," "may," "could," "should," and similar expressions.
These statements relate to, among other things, the expected performance and capabilities of the BMP AI platform; the Company’s ability to successfully complete product development, enter commercial deployment, or scale its technology; future revenues and market expansion; and general strategic direction. All such statements are inherently uncertain and involve a number of risks that could cause actual results to differ materially from those expressed or implied in any forward-looking statement.
NeuralBase AI Ltd. is a fully reporting company with the U.S. Securities and Exchange Commission (SEC) and files annual and quarterly reports, current reports, and other required disclosures. All public filings and disclosures may be reviewed at the SEC’s EDGAR database at www.sec.gov. The Company trades on the OTC Markets under the ticker symbol NBBI.
This press release is not, and should not be construed as, an offer to sell or a solicitation of an offer to buy any securities of NeuralBase AI Ltd. in the United States or in any other jurisdiction. Offers and sales of securities, if any, will be made only pursuant to an effective registration statement or valid exemption under the U.S. Securities Act of 1933, as amended.
Investing in securities traded on the OTC Markets involves significant risk, including potential loss of principal, low liquidity, high volatility, and limited publicly available information. Shares traded on the OTC Markets may be more susceptible to market manipulation or price swings. Investors are strongly advised to conduct their own due diligence, consult a qualified investment advisor, and carefully review all SEC filings prior to making any investment decision.
Media Contact:
Vighnesh Dobale
Chief Executive Officer
ir@neuralbase.ai
(727) 314-3717
View the original release on www.newmediawire.com
